TWiV 949: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Progress toward Poliomyelitis eradication (CDC)
- Polio by the numbers (JID)
- Influenza & COVID-19 vaccination coverage among health care personnel (CDC)
- Phase 1/2a Safety & Immunogenicity of an adenovirus RSV Vaccine (JID)
- Receipt of first & second doses of JYNNEOS vaccine (CDC)
- Distinguishing SARS-CoV-2 persistence and reinfection (CID)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Novavax triggers potent neutralization of Omicron sub-lineages (bioRxiV)
- Association between physical activity & vaccination protective effect (BMJ)
- PAXLOVID patient eligibility screening checklist (FDA)
- COVID-19 outcomes in solid organ transplant recipients who received monoclonal antibodies (Transplantation)
- Omicron BA.2.75.2 exhibits escape from neutralizing antibodies (bioRxiV)
- Tocilizumab vs. Baricitinib in hospitalized patients with severe COVID-19 (CMI)
- Dr. Griffin's treatment guide (pdf)
- Contribute to Floating Doctors fundraiser at PWB
- Letters read on TWiV 949
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Progress toward Poliomyelitis eradication (CDC)
- Polio by the numbers (JID)
- Influenza & COVID-19 vaccination coverage among health care personnel (CDC)
- Phase 1/2a Safety & Immunogenicity of an adenovirus RSV Vaccine (JID)
- Receipt of first & second doses of JYNNEOS vaccine (CDC)
- Distinguishing SARS-CoV-2 persistence and reinfection (CID)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Novavax triggers potent neutralization of Omicron sub-lineages (bioRxiV)
- Association between physical activity & vaccination protective effect (BMJ)
- PAXLOVID patient eligibility screening checklist (FDA)
- COVID-19 outcomes in solid organ transplant recipients who received monoclonal antibodies (Transplantation)
- Omicron BA.2.75.2 exhibits escape from neutralizing antibodies (bioRxiV)
- Tocilizumab vs. Baricitinib in hospitalized patients with severe COVID-19 (CMI)
- Dr. Griffin's treatment guide (pdf)
- Contribute to Floating Doctors fundraiser at PWB
- Letters read on TWiV 949
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.